ALLERGY THERAPEUTICS PLC

Report Publication Announcement • Oct 16, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4567C

Allergy Therapeutics PLC

16 October 2015

16 October 2015

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Annual Report and Accounts

Allergy Therapeutics plc, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that the Annual Report and Accounts for the year ended 30 June 2015 are available on the Company's website in the Investor Relations section. They can be located at:

www.allergytherapeutics.com/media/1216/atl-financial-statements-june-2015.pdf 

Printed copies of the Annual Report and Accounts for the year end 30 June 2015 will be posted to shareholders together with the Notice of the Annual General Meeting on 20 October 2015.

For further information:

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
Panmure Gordon	+44 (0) 20 7886 2500
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway
Victoria Foster Mitchell

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business achieving revenue in the last financial year of £43 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSBRBDGLSBBGUU